OncoMate MSI Dx Analysis System
A comprehensive genomic profiling assay used as a companion diagnostic to select patients for targeted therapies across multiple solid tumors.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
OncoMate MSI Dx Analysis System is an in vitro diagnostic test that uses next-generation sequencing to identify genomic alterations in solid tumors. It is approved by the FDA as a companion diagnostic for multiple targeted therapies across tumor types.
Results from this assay help determine whether a patient is eligible for specific therapies based on the genomic profile of their tumor.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Endometrial Carcinoma (EC) | Microsatellite stable/MSS (Not MSI-High) | MSS (Not Microsatellite instability high/not MSI-H) | KEYTRUDA + LENVIMA |
IVD Manufacturer
This companion diagnostic is performed exclusively at Foundation Medicine's CLIA-certified, CAP-accredited laboratory.
Order this test
If your organization is connected to Casandra, you can place an electronic order for OncoMate MSI Dx Analysis System directly from your existing workflow.
Order via CasandraCasandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.